Tricor 145 mg

145 mg papa hana ʻoniʻoni

Aia ma ka papa papa

mea waiwai - micronized fenofibrate 145 mg,

nā mea hoʻowalewale: hypromellose, sodium docusate, sucrose, sodium lauryl sulfate, lactose monohydrate, microcrystalline silonized cellulose, crospovidone, magnesium stearate.

ukana moku: Opadry OY-B-28920 (polyvinyl waiʻona, titanium dioxide E171, talc, soya bean lecithin, xanthan gum).

ʻO nā papa hana i hana ʻia i kālai ʻia me ke kāʻei kiʻi keʻokeʻo, i kahakaha ʻia me "145" ma kekahi ʻaoʻao a me ka logo ʻoihana ma kēlā ʻaoʻao.

ʻO nā huahana Pharmacological o ka lāʻau Tricor 145 mg

fenofibrate kahi mea o ka waikawa fibroic. ʻO kona hopena i ka ʻōlelo lipid, ka mea i ʻike ʻia i loko o nā kānaka, i hoʻolalelale ʻia e ka hoʻōla ʻana o kahi receptor i hoʻoikaika ʻia e proliferating factor alpha type peroxisome (PPARA).
Ma o ka hana ʻana a ka PPARα, hoʻonui ka fenofibrate i ka nui o ka lipolysis a me ka hoʻopau ʻana i nā hapa momona o TG mai ka punetū koko ma ka hoʻōla ʻana o ka lipoprotein lipase a me ka hoʻemi ʻana i ka hoʻokumu ʻana o ka apoprotein CIII. Hoʻokomo pū ka hoʻonaninani ʻo PPARα i ka hoʻonui ʻana i ke kāpili ʻana o ka apoproteins AI a me II.
ʻO nā hopena i hōʻike ʻia o ka fenofibrate ma LP e alakaʻi i ka emi ʻana o nā hapa o VLDL a me LDL, aia ka apoprotein B, a me ka hoʻonui ʻana o ka hapa HDL, ka mea i loaʻa nā apoproteins AI a me II.
Hoʻohui ʻia, ma ka hoʻololi ʻana i ka synthesis a me ka catabolism o ka hapa VLDL, hoʻonui ka fenofibrate i ka hoʻomaʻemaʻe ʻana o LDL a hoʻemi i ka nui o LDL, ka nui o ka pae me ka atherogen lipoprotein fenotype, kahi e nānā mau ʻia i ka poʻe maʻi ma ka hōʻeha o ka maʻi ʻalani coronary.
I ka wā hoʻāʻo o ka fenofibrate, ua hoʻemi ka nui o ka kolamu ma ka 20-25%, ʻo TG ma ka 40-55%, a me ka kiʻekiʻe o ka HDL cholesterol i hoʻonui ʻia e 10-30%. I loko o nā mea maʻi me ka hypercholesterolemia, kahi i hoʻemi ʻia ai ka pae o ka LDL kolamu ma 20 - 35%, ʻo ka nui o ka hopena e pili ana i ka kolamu e pili ana i ka hoʻemi ʻana o nā hoʻohālikelike o ka kolamu o ka kolamu HDL, ʻo LDL cholesterol a HDL cholesterol a apoprotein B i ka apoprotein AI, kahi hōʻailona o ka hopena atherogenic.
Ma muli o kona hopena ma ka LDL cholesterol a me ka triglycerides, ʻo ka hopena fenofibrate ka hopena maikaʻi ma ka mea maʻi a me ka ʻole o hypercholesterolemia i hui pū ʻia me hypertriglyceridemia, me ka hyperlipoproteinemia lua, ʻo ia ka mea i ʻike ʻia i ka type II diabetes mellitus.
I kēia manawa, ʻaʻohe hopena o nā noi hoʻomanawanui lōʻihi e hōʻike i ka pono o ka pili fenofibrate e pili ana i ka pale mua a me ke kaulike o nā hōʻeha o ka atherosclerosis.
ʻO nā waihona extravascular o ka cholesterol (xanthoma tendinosum et tuberosum) hiki ke hoʻohaʻahaʻa a emi loa i ka hele ʻana i ka wā o ka terapi fenofibrate.
I ka poʻe maʻi me ka kiʻekiʻe o ka fibrinogen level i mālama ʻia me ka fenofibrate, ua ʻike ʻia kahi emi nui i loko o kēia palaki. ʻO nā māka ʻē aʻe o ke kuni ʻana, e like me CRP, ua hōʻemi ʻia me ka mālama fenofibrate.
ʻO ka hopena uricosuric o ka fenofibrate, ka mea e hōʻemi ai i ka hoʻemi ʻana i nā pae waikawa uric ma ka 25%, hiki ke manaʻo e lilo i hopena maikaʻi hou i nā mea maʻi me ka dyslipidemia i hui pū me ka hyperuricemia.
Ua loaʻa i hiki i ka fenofibrate ke hōʻemi i ka hoʻohui platelet i hoʻihoʻi ʻia e ka adenosine diphosphate, acid arachidonic, a me ka epinephrine.
145 mg Aia nā papa tricor i ka fenofibrate i ke ʻano o nanoparticles.
Kapehu
Loaʻa ka ʻike kiʻekiʻe loa i ka plasma koko i nā hola he 2 ma hope o ka lawelawe waha. Kūkulu ka paʻa ʻana o ke kaila koko me ka mālama mau.
ʻAʻole like me nā hoʻomākaukau ʻē aʻe fenofibrate, ka nui loa o ke kao i loko o ka kaila koko a me ka lawe ʻole ʻana i ka lāʻau no ka nui, ka mea i loaʻa i ka nanofarticles fenofibrate, ʻaʻole ia e pili ana i ka kōʻai ʻana o ka meaʻai. No laila, hiki ke hoʻohana ʻia nā papa o Traicor 145 mg ma kahi o ka ʻai kai.
ʻO kahi hōʻike e pili ana i ka lawe ʻana o ka lāʻau, ka mea e hoʻopili ai i ka papa o nā papa heʻomeka 145 mg i nā kāne olakino a me nā wahine ma kahi ʻōpū ʻole a i ka wā o ka ʻai me ka momona momona, hōʻike ʻia ka pili ʻole o ka meaʻai i ka hoʻopili ʻana (AUC a me ka plasma kiʻekiʻe loa) o ka acid fenofibric.
Kahele
He kiʻekiʻe ka hakakā Fenofibric e hoʻopili ana i ka albumin plasma (ʻoi aku ma mua o 99%).
Metabolism a me ka Waihona
Ma hope o ka lawelawe waha, ua hoʻopili koke ʻia ka fenofibrate e nā esterases i ka metabolite ikaika o ka waikui fenofibric. ʻAʻole i ʻike ʻia ka Fenofibrate i loko o ke koko koko. ʻAʻole kahi lupa o Fenofibrate he substrate no ka CYP 3A4 a ʻaʻole i komo i ka metabolism hepatic microsomal.
Hoʻopau ka Fenofibrate i ka nui o ka urine. Ua aneane pau loa ia i loko o 6 lā. Ua hūnā ʻia ia nui ma ke ʻano o ka waikawa fenofibric a me kāna hui pū me ka glucuronide. I nā poʻe maʻi ʻelemakule, ʻaʻole i loli ka nui o ka hoʻopiha plasma.
Nā haʻawina hoʻoliʻika ma hope o ka lawe ʻana i hoʻokahi pākahi a me ke ʻano lōʻihi e hōʻike ana ʻaʻole i ʻōmaʻomaʻo ka fenofibrate e ke kino.
ʻAʻole i hoʻopili ʻia ka waikawa Fenofibric e ka hemodialysis.
ʻO ka hapalua wale o ka waikawa fenofibric mai ka plasma koko he 20 mau hola.

ʻO nā waiwai Pharmacological

Lapaʻau lāʻau

145 mg film Tricor coated coecure he 145 mg o ka micronized fenofibrate ma ke ʻano o nanoparticles.

Kapehu. Ma hope o ka hoʻoponopono waha ʻana o Tricor, 145 mg o Cmax (ka nui o ke kūpaʻa) o ka waikawa fenofibroic i loaʻa ma hope o nā hola 2-4. Me ka hoʻohana mau ʻana, hoʻomau ʻia ka hoʻohuihui o ka waikawa fenofibroic i loko o ka plasma, me ka mau o nā hiʻohiʻona o ka mea maʻi. ʻAʻole like me ka hoʻopuka mua ʻana o ka fenofibrate, Cmax i loko o ka plasma a me ka hopena āpau o ka micofized fenofibrate ma ke ʻano nanoparticles (Tricor 145 mg) kūʻokoʻa i ka ʻai kau meaʻai (no laila, hiki ke lawe ʻia ka lāʻau lapaʻau i kēlā me kēia manawa, me ka ʻole o ka komo o ka meaʻai).

Hoʻopili paʻa nā waikawa Fenofibroic a ʻoi aku ka 99% e hoʻopili ai i ka albumin plasma.

Metabolism a me ka hoʻopā ʻana

Ma hope o ka lawelawe waha, ua hoʻopili koke ʻia ka fenofibrate e nā esterases i ka acid fenofibroic, ʻo ia kāna hana metabolite koʻikoʻi. ʻAʻole ʻike ʻia ka Fenofibrate ma ka plasma. ʻAʻole o Fenofibrate kahi papa i ka CYP3A4, ʻaʻole i komo i ka metabolism microsomal i loko o ka puʻuwai.

Hoʻopau ka Fenofibrate i ka nui o ka urine i ke ʻano o ka waikawa fenofibroic a me nā konuate glucuronide. I loko o 6 lā. hoʻohālikelike ʻia ka fenofibrate. I nā maʻi maʻi maʻi, ʻaʻole e loli ka nui o ka hoʻopiha o ka waikena fenofibroic. ʻO ka hapalua hapalua o nā wa asuma fenofibroic (T1 / 2) he mau hola 20. Ke hōʻike ʻole ʻia ka hemodialysis. Ua hōʻike nā haʻawina Kinetic ʻaʻole i hōʻiliʻili ʻo fenofibrate ma hope o hoʻokahi pākahi a me ka hoʻohana mau ʻana.

Lapaʻau lāʻau

ʻO Tricor kahi mea hoʻohenehene lipid mai ka hui o nā derivatives acid fibroic. Loaʻa i ka Fenofibrate ka hoʻololi i ka ʻike lipid ma ke kino ma muli o ka hoʻihoʻiʻana o nā receptors PPAR-α (alpha receptors e hoʻihoʻi ʻia e ka peroxisome proliferator).

Hoʻonui ka Fenofibrate i ka lipolysis plasma a me ka hoʻopuka ʻana i nā lipoproteins atherogen me ka ʻike kiʻekiʻe o ka triglycerides ma o ka hoʻoulu ʻana i nā receptors PPAR-α, lipoprotein lipase a hōʻemi i ka synthesis o apoprotein C-III (apo C-III). ʻO nā hopena i hōʻike ʻia ma luna nei e pili i ka emi ʻana o nā kikoʻī o LDL a me VLDL, ʻo ia hoʻi ka apoprotein B (apo B), a me ka hoʻonui ʻana i nā kiko o nā huaʻōlelo HDL, kahi e loaʻa ai ka apoprotein A-I (apo A-I) a me apoprotein A-II (apo A-II) . ^ E Ha yM. Eia kekahi, ma muli o ka hoʻoponopono ʻana o ka mau hewa o ka synthesis a me ka catabolism o VLDL, hoʻonui ka fenofibrate i ka hoʻomaʻemaʻe ʻana o LDL a hoʻēmi i nā kiko o nā hapa liʻiliʻi a me ka palu o LDL (e hoʻonui ʻia ana kēia LDL i ʻike ʻia i nā mea maʻi me ka lipotype lipher atherogen a pili pū me ka hiki ʻana o ka CHD).

I ka wā o nā noiʻi haumania, ua hōʻike ʻia ka hoʻokaʻawale ʻana o ka hoʻohanaʻana i ka fenofibrate i ka pae o ka kolamu ma ka 20-25% a me ka triglycerides e ka 40-55% me ka piʻi o ka pae o ka HDL-C ma ka 10-30%. I ka poʻe maʻi me ka hypercholesterolemia, kahi e hōʻemi ʻia ai ke kiʻekiʻe o Chs-LDL e ka 20-35%, ka hoʻohana ʻana o ka fenofibrate i ka hōʻemi i nā kāwili: ʻo ka huina Chs / Chs-HDL, Chs-LDL / Chs-HDL a me apo B / apo A-I, he mau mea hōʻailona o ka atherogenic. Hoʻopilikia.

ʻAʻohe manaʻo e hiki i nā fibrates ke hōʻemi i ka pinepine o nā hanana i pili i ka maʻi naʻau coronary, akā ʻaʻohe hōʻailona no ka hōʻemi o ka nui o ka make ma ka maʻamau a i ʻole ke hōʻemi tuarua ʻana i ka maʻi cardiovascular.

I ka wā o ka mālama ʻana me ka fenofibrate, ka nui o nā huna maʻa o XC (tendon a me tubanthous xanthomas) hiki ke hoʻohaʻahaʻa loa a emi loa. I nā maʻi me nā kiʻekiʻe o ka fibrinogen i mālama ʻia me ka fenofibrate, ua ʻike ʻia kahi emi nui i loko o kēia hōkuhi, a me nā mea maʻi me nā kiʻekiʻe o ka lipoproteins. I ka mālamaʻana i ka fenofibrate, ua nānā ʻia kahi emi o ka neʻe ʻana o ka protein C-reactive a me nā mākaʻi ʻē aʻe o ka mumū.

No ka poʻe maʻi me ka dyslipidemia a me ka hyperuricemia, ʻoi aku ka maikaʻi aʻe o ka fenofibrate i loaʻa ka hopena uricosuric, ka mea e hōʻemi ai i ka neʻe o ka uric acid ma kahi o 25%.

I loko o kahi noiʻi haukapila, ua hōʻike ʻia ka fenofibrate e hōʻemi i ka hoʻohui ʻana o platelet i kumu o ka adenosine diphosphate, acid arachidonic, a me epinephrine.

Nā hōʻailona no ka hoʻohana ʻana

ʻO ka hoʻonuiʻana i nā meaʻai a me nā lāʻau lapaʻau ʻole

(ka hana kino, ke kaumaha o ke kaumaha) ma nā ʻano aʻe:

hypertriglyceridemia koʻikoʻi me a ʻole ʻole kolokole haʻahaʻa

- i hui pū ʻia ka hyperlipidemia ma mua o nā contraindications a i ʻole ka intolerance i nā statins

- i hui pū ʻia me hyperlipidemia i nā maʻi me ka puʻuwai cardiovascular kiʻekiʻe i ka hoʻohui ʻana i nā statins me ka ʻike ʻole i ka ʻoiaʻiʻo i ka hoʻoponopono ʻana i ka triglycerides a me ka cholesterol kiʻekiʻe kiʻekiʻe

ʻLoe a me ke kākele

Lawe ʻia ka lāʻau lapaʻau Tricor 145 mg i kēlā me kēia manawa o ka lā, me ka nānā ʻole o ka ʻai ʻana, e ʻai nui ʻia ka papa me ka ʻaʻa ʻole ʻana, me kahi aniani o ka wai.

I ka hui ʻana me kahi mea ʻai, Tricor 145 mg i kuhikuhi i nā papa lōʻihi, ʻo ka pono o ka mea e nānā maʻamau.

Loiloi ka hopena Therapeutic i ka hoʻohana ʻana i nā waiwai o nā ngana lipid (ka nui a me ka kolamu, ka haʻahaʻa haʻahaʻa haʻahaʻa, triglycerides).

Inā ma loko o 3 mau mahina ʻaʻole he holomua o ka ʻōlelo lipid, pono e hāʻawi ʻia i ka noʻonoʻo e koho ai i kahi lāʻau hou a i ʻole he lāʻau lapaʻau hou.

Kuhi ʻia nā ʻōpio i 1 papa o Tricor 145 mg 1 manawa i kēlā me kēia lā. ʻO nā mea maʻi e lawe ana i 1 mau kapule o ka fenofibrate 200 mg hiki ke hoʻololi i ka lawe ʻana i 1 papa o Tricor 145 mg i kēlā me kēia lā me ka ʻole o ka hoʻoponopono hou ʻia.

ʻO nā mea maʻi e lawe i hoʻokahi papa o fenofibrate 160 mg i kēlā me kēia lā, hiki ke hoʻololi i ka lawe ʻana i ka papa 1 o Tricor 145 mg me ka loaʻa ʻole o ka hoʻoponopono hou aku.

ʻO nā maʻi maʻi me ka hea ʻole o ka pale, kauoha ʻia ke ʻano pākaukau maʻamau.

Ka hoʻohana o ka lāʻau lapaʻau i nā mea maʻi me nā maʻi pūpū ʻaʻole i aʻo ʻia.

Nā hopena hopena

ʻO nā hopena hope loa i ʻike ʻia i ka wā hoʻokolohua lapaʻau hoʻomalu ʻia e ka pletebo (n = 2344):

- ʻeha o ka ʻōpū, nilo, ka luaʻi, ka ʻōpū, ke kaʻahele, ka maʻi ʻōpū (ʻoluʻolu)

- ka kiʻekiʻe o nā transaminases

- thrombosis vein hohonu, pulmonary thromboembolism

- ka hopena o ke ʻano hypersensitivity: ʻohi, kahe, urticaria

- myalgia, myositis, humuhumu liki, nāwaliwali o ka naʻau

- hoʻonui i nā kiʻekiʻe o ka mea hana i loko o ke koko

- hōʻemi i ka pae hemoglobin, hoʻoemi i nā hoʻolaha o leukocytes

- alopecia, ʻano photosensitivity

- ke piʻi nui o ka pae o ka urea i ke koko koko

- ʻehaʻeha, kaumaha

Nā hopena ʻaoʻao i ʻike ʻia i ka wā o ka hoʻohana ʻana ma hope o ka mākeke (ʻike pinepine ʻole ʻia).

- nā jaundice, nā hoʻopiʻi cholelithiasis (e.g. cholecystitis, cholangitis, colic biliary)

nā hopena ʻeha hoʻonā (e.g., erythema multiforme, Stevens-Johnson syndrome, ka maʻi pākēneka epidermal)

Ka hoʻohana ʻana o ka lāʻau lapaʻau Tricor 145 mg

I ka hui pū ʻana me ka papa lāʻau, mālama ʻia ka lāʻau no ka mālama ʻana i ka wā lōʻihi, ʻo ka hiki ke mālama ʻia ka wā i ʻike ʻia e ka hoʻoholo ʻana o ka pae o ka lipids i loko o ke koko serum (kolamu piha, LDL cholesterol, TG).
Inā ma hope o ka hoʻohana ʻana i ka lāʻau lapaʻau no kekahi mau mahina (no ka laʻana 3 mau mahina), ʻaʻole i emi ka nui o nā lipids i loko o ka serum koko, pono pono e noʻonoʻo i ka koho hou ʻia o ka lāʻau lapaʻau hou a i nā ʻano lāʻau ʻē aʻe paha.
Nā ʻōpala
Nā pākeke
ʻO ka dosis i ʻōlelo ʻia e pili ana i ka 145 mg (1 papa) i hoʻokahi lā. ʻO nā mea maʻi e lawe fenofibrate ma ke ʻano o 200 mg hiki ke hoʻololi ʻia me 1 papa o Tricor 145 mg me ke koho ʻole ʻia o ka nui.
ʻO nā maʻi maʻi
No nā poʻe maʻi kahiko, ua kauoha ʻia nā maʻi lāʻau maʻamau.
ʻO nā mea maʻi me ka maikaʻi ʻole o ka pūpū
ʻO nā maʻi me ka pilikia ʻole e pono ai ke hōʻemi i ka ʻeha. Kuhi ʻia nā mea maʻi e lawe i nā lāʻau lapaʻau e loaʻa ana nā haʻahaʻa haʻahaʻa o ka fenofibrate (100 mg a 67 mg).
E na keiki
Tricor 145 mg a contraindicated no ka mālama ʻana i nā keiki.
Maʻi maʻi
ʻAʻole i aʻo ʻia ka hoʻohana ʻana o ka lāʻau i nā maʻi me nā maʻi o ka naʻau.
Ke ʻano o ka noi
E hoʻopau ʻia nā papa āpau me kahi ipu wai.
145 mg ʻO nā papa Traicor hiki ke lawe i kēlā me kēia manawa i ka lā, kahi o ka ʻai ʻana o ka meaʻai.

Nā Pākuʻi Tricor 145 mg

Ka maʻi o ka Hepatic (e pili ana i ka cirrhosis biliary), ka papakū papau, ke kamaliʻi, hypersensitivity i ka fenofibrate a i nā mea ʻē aʻe o ka lāʻau lapaʻau, photosensitivity a i ʻole ka phototoxic i ka wā o ka mālama ʻana me nā fibrates a i ka ketoprofen i ke au o ka wā i hala, ka maʻi ʻeha puhipuhi (maʻi o ka gallstone).
ʻAʻole pono e lawe ʻia ʻo Tricor 145 mg i nā mea maʻi me kahi alerine i ka pata pīpī a soya lecithin, a i ʻole nā ​​mea e pili ana i ka hopena (hiki i nā hopena o ke ʻano hypersensitivity).

Nā hopena maikaʻi o ka lāʻau lapaʻau Tricor 145 mg

Hōʻike nā hopena ʻaoʻao e ke alapine me kēia ala: pinepine pinepine (1/10), pinepine (1/100, ≤1 / 10), pinepine, (1/1000, ≤1 / 100), ʻano liʻiliʻi (1/10 000, ≤1 / 1000) luhi loa (1/100 000, ≤1 / 10 000), me nā hihia huna.
Mai ka gastrointestinal tract
I ka manawa pinepine: ka ʻeha o ka ʻōpū, ke kuʻi ʻana, ka luaʻi ʻana, ka ʻōpū a me ka lemulewa, maʻalahi i ka ʻeha.
ʻO ka maʻamau: ʻo ka pancreatitis.
Ma ka ʻāpana o ka ate a me ka pāpaʻi biliary
I ka manawa pinepine: he hoʻonui haʻahaʻa o nā transaminases serum (e ʻike i ke KĀʻOHU SPECIALE).
ʻO ka maʻamau: ʻo ka hoʻokumu ʻana i nā pōhaku i loko o kahi pīpī.
Loaʻa loa: nā hihia o ka hepatitis. Inā hōʻike ʻia nā hōʻailona (e, jaundice, itching) i ka loaʻa ʻana o ka hepatitis, pono e hana ʻia nā hoʻokolohua hōʻoia e hōʻoia i ka hoʻomau ʻana a, inā pono, hoʻokuʻu i ka lāʻau (ʻike i ka INAHU KANA.
Ma ka ʻāpana o ka ʻili a me ke kiko
Mea ʻole: kūʻai, ʻeha, hives, a i ʻole nā ​​mea photosensitivity.
Aele: alopecia.
Kēia loa: photosensitivity o ka ʻili me ka erythema, ke ʻano o nā vesicles a i nā nodules hoʻi i nā wahi o ka ʻili i hōʻike ʻia i ka lā a me ka radiation ultraviolet artipeti paha i kekahi mau hihia (ʻoi aku ma hope o he mau mahina o ka hoʻohana me ka ʻole o nā hoʻopiʻi).
Mai ka ʻōnaehana musculoskeletal
Kūkulu loa: hoʻokaʻawale i myalgia, myositis, ʻehaʻīku a me ka nāwaliwali o ka naʻau.
Luhi loa: rhabdomyolysis.
Mai ka pūnaehana cardiovascular
ʻO ka maʻamau: thromboembolism venous (pulmonary embolism, hohonu hohonu urinolino).
Ma ka ʻāpana o ka ʻōnaehana koko a me ka ʻōnaehana lymphatic
Kākela: loaʻa kahi hāʻule o ka hemoglobin a me nā keʻena koko keʻokeʻo.
Mai ka pūnaehana pili ʻana
A pili pinepine: nāwaliwali pilikino, nā ʻeha.
Ma ka ʻaoʻao o ka ʻōnaehana hanu, ka umauma a me ka mediastinum
Nui loa kaʻai: nā paila interstitial.
Nā hopena noiʻi
Hoʻopau maʻamau: hoʻonui i ka serum creatinine a me urea.

ʻO nā kauoha kūikawā no ka hoʻohana ʻana i ka lāʻau lapaʻau Tricor 145 mg

Hoʻomaopopo iki ka noho ʻana o Tricor 145 mg i ka hoʻoili ʻia ʻana o nā hopena hanana kūlike e like me ke hypertension (hypertension) a me ka ulaula.
Ma ka hihia o ka hypercholesterolemia kūloko, ma mua o ka hoʻomaka ʻana o ka mālama ʻana me TRICOR 145 mg, pono e hoʻomaʻamaʻa maikaʻi i nā ʻano i hōʻeha ʻia a i ʻole e hoʻopau i nā kumu ʻē aʻe, e like me ka decompensated type II diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemia (no ka laʻana, me ka myeloma ), hyperbilirubinemia, pharmacotherapy (waha i kūlohelohe, corticosteroids, antihypertensive lāʻau lapaʻau, protease inhibitors no ka mālama ʻana i ka maʻi o ka maʻi HIV), ʻalowa.
Pono ka hopena o ka mālama ʻana ma o ka hoʻoholo ʻana i ka pae o lipids ma ka serum o ke koko (kolamu holoʻokoʻa, LDL, TG). Inā ʻaʻole i hoʻokō ʻia ka hopena kūpono no kekahi mau mahina (no ka laʻana, 3 mau mahina) pono e noʻonoʻo e pili ana i ke koho hou ʻana o nā lāʻau lapaʻau hou a i ʻole nā ​​ʻano lāʻau ʻē aʻe.
I ka poʻe maʻi me ka hyperlipidemia e lawe nei i ka hoʻomākaukau ʻana o ka estrogen a i ʻole nā ​​ʻāpana ʻawaʻī e pili ana i ka estrogens, pono ia e nānā inā he koʻikoʻi nui ka hyperlipidemia a me ka puka kumu mua, ʻoiai ka hoʻohana ʻana o ka estrogens waha e hoʻonui i ka pae lipid.
Hālina hana
E like me ka hoʻohana ʻana o nā lāʻau lapaʻau lipid-haʻahaʻa, ua ʻike ʻia kahi hoʻonui o ka hana transaminase i kekahi mau mea maʻi. I ka hapa nui, he transient, light a me ka asymptomatic. Hoʻomaopopo ʻia e nānā i ka hana o nā transaminases i kēlā me kēia 3 mau mahina i ka 12 mau mahina o ka mālama ʻana. Pono e nānā i ke kūlana o nā maʻi i hōʻike i ka piʻi o ke kiʻekiʻe o ka transaminases. Me ka hoʻonui ʻana o ka pae o AlAT a me AsAT e oi aku ma mua o 3 mau manawa i hoʻohālikelike ʻia me ka palena palena kiʻekiʻe o ka maʻamau, pono e hoʻokuʻu ʻia kēia lāʻau lapaʻau.
ʻO ka pancreatitis
I nā maʻi āpau nāna i lawe i ka fenofibrate, ua ʻike ʻia nā hihia o ka pancreatitis. ʻO ia ka hopena e hopena paha i ka mālama ʻana i ka hana ma ka maʻi me nā maʻi hypertriglyceridemia koʻikoʻi, ka hopena pololei o ka lāʻau a i ʻole no kekahi kumu ʻē aʻe, no ka laʻana, he pōhaku i loko o nā dile bile a iʻa paha i nā dile bile maʻamau.
Hoʻoikaika
ʻO ka huʻuleʻawa o ka naʻau, e komo pū ana me nā hihia he nui loa o ka rhabdomyolysis, i ʻike ʻia me nā fibrates a me nā lāʻau lapaʻau ʻē aʻe. Hoʻonui ʻia ke alapine me ka hypoalbuminemia a i ʻole hoʻokiki ʻole. ʻO ka hopena hōʻona i ka ʻeha ma nā maʻi i nā maʻi me ka hoʻokaʻawale i ka myalgia, nā hōʻeha a me ka nāwaliwali o ka naʻau, pū me ka hoʻonui ʻia ʻana o ka CPK (5 mau manawa i hoʻohālikelike ʻia me ke ʻano). I kēia mau hihia, pono e hoʻoneʻe ʻia ka mālama ʻana me TRICOR 145 mg.
Inā aia nā mea e hoʻoholo i ka hiki ʻana i ka myopathy a me / a rhabdomyolysis hoʻi, me ka makahiki o ka 70, nā maʻi ʻeha hoʻoilina i ka mea maʻi a ʻohana paha, nā maʻi maʻi, hypothyroidism, a i ʻole hōʻino wai, hiki i nā mea maʻi ke piʻi nui aʻe i ka hoʻomohala ʻana i ka rhabdomyolysis. I kēlā mau maʻi maʻi, he mea pono e loiloi pono i ka pōmaikaʻi a me ka hōʻemi o ka mālama ʻana me Triicor 145 mg.
Hiki ke hoʻonui ʻia ka hopena o ka hopena o ka ʻawaʻawa ma ke ʻano he mea hoʻohālikelike ʻia ka lāʻau i ka manawa like me kekahi fibrate a i ʻole HMG-CoA reductase inhibitor, ʻoi aku hoʻi i mua o nā maʻi ʻeha puʻukahi concomitant. No laila, ʻoi aku e kuhikuhi i ka hui pū ʻana o ka fenofibrate a statin i nā poʻe maʻi me ka dyslipidemia i hoʻohui pū ʻia a me ka hopena o ka maʻi cardiovascular ma ka waiho ʻole ʻana o ka mōʻaukala o nā maʻi ʻeha a hoʻokō ka mālama ʻana ma lalo o ka nānā kiaʻi ʻana i ka hopena hoʻopōmaikaʻi hiki i nā ʻeha.
Hola a kaʻili
Pono e hoʻokuʻu ʻia ka hoʻomaikaʻi inā hoʻonui ʻia ka pae creatinine ma mua o 50% e hoʻohālikelike ʻia me ka palena palena kiʻekiʻe o ka maʻamau. Hoʻomaopopo ʻia e noʻonoʻo i ka pono o ka nānā ʻana i nā pae creatinine i nā mahina mua ma hope o ka hoʻomaka ʻana o ka hoʻomaʻamaʻa.
Tricor 145 mg loaʻa i ka lactose, no laila, nā mea maʻi me nā maʻi hoʻoilina e like me ka intolerance galactose, ka hemahema o Lapp lactase a i ʻole nā ​​kuhi glucose-galactose e lawe i kēia lāʻau.
Tricor 145 mg loaʻa i ka sucrose, no laila, ʻo nā mea maʻi me nā maʻi hoʻohemo e like me ka frolose intolerance, glucose-galactose malabsorption a i ʻole makemake ʻia ka sucrose-isomaltase e lawe i kēia lāʻau.
Hoʻohana i ka wā hāpai a me ka lactation
ʻAʻole lawa nā ʻikepili lawa i ka hoʻohana ʻana i ka fenofibrate i ka wā hāpai. ʻAʻole hoʻokū ʻia nā haʻawina holoholona i nā hopena teratogenic. Ua ʻike ʻia nā hopena Embryotoxic me nā mea laʻala i nā mea ʻino i ka makuahine. ʻAʻole maopopo ka ʻike mau ʻia o ka poʻe no laila, no laila, hiki ke hoʻohana ʻia ʻo Tricor 145 mg i ka wā hapai ma hope o ka loiloi ʻana o ka hopena o ka pōmaikaʻi / hopena pākuʻi.
ʻAʻohe ʻikepili i ka hoʻokuʻu ʻana o ka fenofibrate a me / a i kāna mau metabolites i loko o ka waiū waiu, no laila, ʻaʻole e lawe ʻia ʻo Tricor 145 mg e nā makuahine e hoʻomaʻamaʻa nei.
ʻO ka hiki ke hāpai i ka hopena o ka hopena i ka wā e hoʻokele ai i nā kaʻa a hana paha me nā hana ʻē aʻe. ʻAʻole i loaʻa ka hopena.

Nā Pākaʻina ʻOi aku ka hōʻeha ʻĀpana 145 mg

Anticoagulants oral
Hoʻonui ka Fenofibrate i ka hopena o nā anticoagulants o ka waha a hoʻonui i ka hopena o ke kahe. Manaʻo ʻia e hoʻemi ʻia ka nui o nā anticoagulants e ka 1/3 i ka hoʻomaka ʻana o ka mālama ʻana a laila e piʻi lohi ʻia, inā pono, ma lalo o ka hoʻokele ʻana o INR (ʻo ka pae ʻāina maʻamau maʻamau).
Cyclosporin
Nui nā hihia koʻikoʻi o ka hana renal i hoʻomaopopo ʻia me ka hoʻohana pū ʻana o ka fenofibrate a me ka cyclosporine, no laila, ma ia mau mea maʻi, pono e kiaʻi pono ʻia ka hana o ka māka. Pono e hoʻoneʻe ʻia ka lāʻau lapaʻau me TRICOR 145 mg e pili ai i nā kaʻe ʻana o ka pale ʻana o nā ʻāpana laboratorium.
ʻO ka HMG-CoA reductase inhibitors a me nā fibrates ʻē aʻe
Hoʻonui ʻia ka hopena o ka hōʻeha ʻana i ka pōʻino o ka pōʻino a ʻoiai e hoʻohana ʻia me ka HMG-CoA reductase inhibitors a i ʻole nā ​​fibrates. Pono e hui pū ʻia me kēia me ka makaʻala e kiaʻi pono i ka nānā ʻana o nā hōʻailona o ka hopena o ke kinipona ma nā uaua (e ʻike i ke KĀʻOHU AUPUNI).
Enzymes Cytochrome P450
Ke noiʻi i loko o vitro ke hoʻohana nei i ka microsomes hepatic kanaka, fenofibrate a me ka acidofofric acid e ʻaʻole i hoʻomālamalama i ka cytochrome (CYP) P450 isoforms CYP 3A4, CYP 2D6, CYP 2E1 a i ʻole CYP 1A2. Kuhi lākou i nā mākeke palupalu o CYP 2C19 a me CYP 2A6 a loaʻa i kahi hopena inhibitory nāwaliwali a hōʻemi haʻahaʻa paha ma ka CYP 2C9 i nā kikowaʻe therapeutic, pono e noʻonoʻo i ka wā e lawelawe ʻia me nā lāʻau lapaʻau e metamine me ke komo ʻana o kēia isofrome P450.